PRTG Portage Biotech Inc

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of October 2024

Commission File Number: 001-40086

Portage Biotech Inc.

(Translation of registrant’s name into English)

Clarence Thomas Building, P.O. Box 4649, Road Town, Tortola, British Virgin Islands, VG1110

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

INCORPORATION BY REFERENCE

This report on Form 6-K (including any exhibits attached hereto) shall be deemed to be incorporated by reference into the registration statement on Form S-8 (File No. 333-275842) of Portage Biotech Inc. (including any prospectuses forming a part of such registration statement) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. 

Management Changes

On September 30, 2024, Allan Shaw, Chief Financial Officer of Portage Biotech Inc. (the “Company”), and Joseph Ciavarella, accounting consultant to the Company, departed from the Company.

On September 30, 2024, Andrea Park, as Chief Financial Officer, and Adam Melero, as Controller, joined the Company.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

PORTAGE BIOTECH INC.

Portage Biotech (NASDAQ:PRTG)
Historical Stock Chart
Von Okt 2024 bis Nov 2024

Portage Biotech (NASDAQ:PRTG)
Historical Stock Chart
Von Nov 2023 bis Nov 2024